JP7622229B2 - N-(2-(4-シアノチアゾリジン-3-イル)-2-オキソエチル)-キノリン-4-カルボキサミド - Google Patents

N-(2-(4-シアノチアゾリジン-3-イル)-2-オキソエチル)-キノリン-4-カルボキサミド Download PDF

Info

Publication number
JP7622229B2
JP7622229B2 JP2023536454A JP2023536454A JP7622229B2 JP 7622229 B2 JP7622229 B2 JP 7622229B2 JP 2023536454 A JP2023536454 A JP 2023536454A JP 2023536454 A JP2023536454 A JP 2023536454A JP 7622229 B2 JP7622229 B2 JP 7622229B2
Authority
JP
Japan
Prior art keywords
alkyl
cyanothiazolidin
oxoethyl
carboxamide
quinoline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023536454A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023554405A5 (cg-RX-API-DMAC7.html
JP2023554405A (ja
Inventor
ブローナルト,ヨーナス
ホルム,ビョルン
ヨハンソン,マリア
カールソン,オッレ
ローラン クネール,ダニエル
ノルドクヴィスト,アンネリ
ジョン シェパード,ロバート
スワンソン,マリアン
トンバーグ,アナ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of JP2023554405A publication Critical patent/JP2023554405A/ja
Publication of JP2023554405A5 publication Critical patent/JP2023554405A5/ja
Priority to JP2025005438A priority Critical patent/JP7744538B2/ja
Application granted granted Critical
Publication of JP7622229B2 publication Critical patent/JP7622229B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2023536454A 2020-12-17 2021-12-16 N-(2-(4-シアノチアゾリジン-3-イル)-2-オキソエチル)-キノリン-4-カルボキサミド Active JP7622229B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025005438A JP7744538B2 (ja) 2020-12-17 2025-01-15 N-(2-(4-シアノチアゾリジン-3-イル)-2-オキソエチル)-キノリン-4-カルボキサミド

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063126593P 2020-12-17 2020-12-17
US63/126,593 2020-12-17
PCT/IB2021/061839 WO2022130270A1 (en) 2020-12-17 2021-12-16 N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)- quinoline-4-carboxamides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025005438A Division JP7744538B2 (ja) 2020-12-17 2025-01-15 N-(2-(4-シアノチアゾリジン-3-イル)-2-オキソエチル)-キノリン-4-カルボキサミド

Publications (3)

Publication Number Publication Date
JP2023554405A JP2023554405A (ja) 2023-12-27
JP2023554405A5 JP2023554405A5 (cg-RX-API-DMAC7.html) 2024-11-06
JP7622229B2 true JP7622229B2 (ja) 2025-01-27

Family

ID=79164845

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023536454A Active JP7622229B2 (ja) 2020-12-17 2021-12-16 N-(2-(4-シアノチアゾリジン-3-イル)-2-オキソエチル)-キノリン-4-カルボキサミド
JP2025005438A Active JP7744538B2 (ja) 2020-12-17 2025-01-15 N-(2-(4-シアノチアゾリジン-3-イル)-2-オキソエチル)-キノリン-4-カルボキサミド

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025005438A Active JP7744538B2 (ja) 2020-12-17 2025-01-15 N-(2-(4-シアノチアゾリジン-3-イル)-2-オキソエチル)-キノリン-4-カルボキサミド

Country Status (20)

Country Link
US (2) US20240101549A1 (cg-RX-API-DMAC7.html)
EP (1) EP4263535A1 (cg-RX-API-DMAC7.html)
JP (2) JP7622229B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230122080A (cg-RX-API-DMAC7.html)
CN (1) CN116745291B (cg-RX-API-DMAC7.html)
AR (1) AR124379A1 (cg-RX-API-DMAC7.html)
AU (2) AU2021403827B2 (cg-RX-API-DMAC7.html)
CA (1) CA3204318A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023001763A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023008921A2 (cg-RX-API-DMAC7.html)
CR (1) CR20230314A (cg-RX-API-DMAC7.html)
DO (1) DOP2023000124A (cg-RX-API-DMAC7.html)
EC (1) ECSP23053033A (cg-RX-API-DMAC7.html)
IL (1) IL303655A (cg-RX-API-DMAC7.html)
MX (1) MX2023007287A (cg-RX-API-DMAC7.html)
PE (1) PE20232046A1 (cg-RX-API-DMAC7.html)
SA (1) SA523441175B1 (cg-RX-API-DMAC7.html)
TW (1) TW202239407A (cg-RX-API-DMAC7.html)
UY (1) UY39569A (cg-RX-API-DMAC7.html)
WO (1) WO2022130270A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY39569A (es) * 2020-12-17 2022-07-29 Astrazeneca Ab N-(2-(4-cianotiazolidin-3-il)-2-oxoetil)- quinolin-4-carboxamidas
AU2023288645A1 (en) * 2022-06-21 2025-02-13 Astrazeneca Ab Solid-state forms of n-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)- 6-morpholinoquinoline-4-carboxamide
CN119562951A (zh) * 2022-06-21 2025-03-04 阿斯利康(瑞典)有限公司 N-(2-(4-氰基噻唑烷-3-基)-2-氧代乙基)-喹啉-4-甲酰胺
WO2026119802A1 (en) 2024-12-02 2026-06-11 Astrazeneca Ab Dosing regimen for the treatment of fap-mediated conditions

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003515585A (ja) 1999-11-30 2003-05-07 フェリング ベスローテン フェンノートシャップ 新規抗糖尿病薬
JP2009507011A (ja) 2005-09-02 2009-02-19 フェリング ベスローテン フェンノートシャップ Fap阻害剤
WO2013107820A1 (en) 2012-01-17 2013-07-25 Universiteit Antwerpen Novel fap inhibitors

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW521072B (en) 1997-06-02 2003-02-21 Meiji Seika Kaisha 4-quinolinol derivatives and fungicides containing the same as an active ingredient used for agriculture and horticulture
FR2795726A1 (fr) 1999-06-30 2001-01-05 Aventis Cropscience Sa Nouveaux pyrazoles fongicides
DE10006453A1 (de) 2000-02-14 2001-08-16 Bayer Ag Piperidylcarbonsäuren als Integrinantagonisten
GB0010183D0 (en) 2000-04-26 2000-06-14 Ferring Bv Inhibitors of dipeptidyl peptidase IV
GB0010188D0 (en) 2000-04-26 2000-06-14 Ferring Bv Inhibitors of dipeptidyl peptidase IV
AU2001277754B2 (en) 2000-08-10 2005-09-29 Mitsubishi Tanabe Pharma Corporation Proline derivatives and use thereof as drugs
JP2003026698A (ja) 2000-09-27 2003-01-29 Tokyo Inst Of Technol 新規化合物、固定化物及び蛋白質のスクリーニング方法
GB0125445D0 (en) 2001-10-23 2001-12-12 Ferring Bv Protease Inhibitors
AU2004207731B2 (en) 2003-01-31 2009-08-13 Sanwa Kagaku Kenkyusho Co., Ltd. Compound inhibiting dipeptidyl peptidase iv
EP2210607B1 (en) * 2003-09-26 2011-08-17 Exelixis Inc. N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
WO2005087742A1 (en) 2004-03-08 2005-09-22 Exelixis, Inc. Metabolic kinase modulators and methods of use as pesticides
TWI366438B (en) 2004-08-12 2012-06-21 Ishihara Sangyo Kaisha Fungicidal composition containing acid amide derivative
WO2007017423A2 (en) 2005-08-11 2007-02-15 F. Hoffmann-La Roche Ag Pharmaceutical composition comprising a dpp-iv inhibitor
JP2010510246A (ja) 2006-11-21 2010-04-02 スミスクライン ビーチャム コーポレーション アミド抗ウイルス化合物
CN102884059B (zh) 2010-03-11 2015-08-26 大日本住友制药株式会社 N-酰基环胺衍生物或其可药用盐
EP4706663A3 (en) 2011-08-30 2026-05-20 Trustees Of Tufts College FAP-ACTIVATED PROTEASOME INHIBITORS USED TO TREAT SOLID TUMORS
UA110862C2 (uk) 2011-10-07 2016-02-25 Ф. Хоффманн-Ля Рош Аг Похідні етинілу як алостеричні модулятори метаботропного рецептора глутамату mglur 5
EP2874632B1 (en) 2012-07-23 2020-06-17 Sphaera Pharma Pte. Ltd Triazine compound having pi3k-alpha and mtor inhibiting activity
MX2016012573A (es) 2014-03-28 2018-02-19 Sunshine Lake Pharma Co Ltd Compuestos de dihidropirimidina y su aplicacion en productos farmaceuticos.
JP2017513954A (ja) 2014-04-22 2017-06-01 ニンバス アイリス, インコーポレイテッド Irak阻害剤およびその使用
AU2015315174B2 (en) 2014-09-10 2019-12-12 Epizyme, Inc. Smyd inhibitors
WO2016061751A1 (en) * 2014-10-22 2016-04-28 Merck Sharp & Dohme Corp. Ethyl n-boc piperidinyl pyrazolo pyridones as janus kinase inhibitors
WO2017189569A1 (en) 2016-04-25 2017-11-02 Trustees Of Tufts College Multimediator dpp4 and fap inhibitors, and uses related thereto
CN118359610A (zh) 2016-09-16 2024-07-19 生命医药有限责任公司 Menin-mll相互作用的抑制剂
WO2018161033A1 (en) 2017-03-02 2018-09-07 Wright, Adrian Small molecule ire1-alpha inhibitors
CN108690043B (zh) 2017-04-11 2019-10-18 东莞东阳光科研发有限公司 喹啉类衍生物及其制备方法和用途
US11358940B2 (en) 2017-04-20 2022-06-14 The Regents Of The University Of California K-Ras modulators
US11584744B2 (en) 2017-06-23 2023-02-21 University Of Washington Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them
JP7365332B2 (ja) 2017-08-07 2023-10-19 ジョイント・ストック・カンパニー “バイオキャド” Cdk8/19阻害薬としての新規ヘテロ環式化合物
EP3700527A4 (en) 2017-10-25 2021-03-10 Children's Medical Center Corporation PAPD5 INHIBITORS AND METHOD OF USING THEM
AU2018386298B2 (en) 2017-12-15 2023-09-07 Praxis Biotech LLC Inhibitors of fibroblast activation protein
JP2021506862A (ja) 2017-12-19 2021-02-22 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung Tlr7/8アンタゴニストおよびそれらの使用
PH12020551205A1 (en) 2018-02-06 2021-04-19 Univ Heidelberg Fap inhibitors
SG11202100818RA (en) 2018-07-31 2021-02-25 Merck Patent Gmbh Tlr7/8 antagonists and uses thereof
US12662494B2 (en) 2018-08-08 2026-06-23 Sumitomo Pharma Co., Ltd. Optically active bridged piperidine derivative
TWI815954B (zh) 2018-08-27 2023-09-21 日商住友製藥股份有限公司 光學活性氮雜雙環衍生物
US10815241B2 (en) 2018-08-27 2020-10-27 Sumitomo Dainippon Pharma Co., Ltd. Optically active azabicyclo ring derivative
CN113811529A (zh) * 2018-12-21 2021-12-17 普拉西斯生物技术有限责任公司 成纤维细胞激活蛋白抑制剂
US12559487B2 (en) 2019-09-27 2026-02-24 Sumitomo Pharma Co., Ltd. Crosslinked optically active secondary amine derivative
BR112022008041A2 (pt) 2019-11-06 2022-08-16 Yuhan Corp Compostos de pirrolidina e piperidina
UY39569A (es) * 2020-12-17 2022-07-29 Astrazeneca Ab N-(2-(4-cianotiazolidin-3-il)-2-oxoetil)- quinolin-4-carboxamidas

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003515585A (ja) 1999-11-30 2003-05-07 フェリング ベスローテン フェンノートシャップ 新規抗糖尿病薬
JP2009507011A (ja) 2005-09-02 2009-02-19 フェリング ベスローテン フェンノートシャップ Fap阻害剤
WO2013107820A1 (en) 2012-01-17 2013-07-25 Universiteit Antwerpen Novel fap inhibitors

Also Published As

Publication number Publication date
DOP2023000124A (es) 2023-07-09
US20240101549A1 (en) 2024-03-28
MX2023007287A (es) 2023-07-03
WO2022130270A1 (en) 2022-06-23
EP4263535A1 (en) 2023-10-25
AU2021403827A1 (en) 2023-07-27
JP7744538B2 (ja) 2025-09-25
CO2023008921A2 (es) 2023-07-21
AU2021403827B2 (en) 2024-07-25
JP2025081297A (ja) 2025-05-27
ECSP23053033A (es) 2023-08-31
TW202239407A (zh) 2022-10-16
UY39569A (es) 2022-07-29
US11858924B2 (en) 2024-01-02
CL2023001763A1 (es) 2023-11-17
CN116745291B (zh) 2026-06-30
IL303655A (en) 2023-08-01
PE20232046A1 (es) 2023-12-27
CR20230314A (es) 2023-08-18
CA3204318A1 (en) 2022-06-23
US20230312550A1 (en) 2023-10-05
KR20230122080A (ko) 2023-08-22
AU2021403827A9 (en) 2024-10-17
SA523441175B1 (ar) 2024-08-29
AU2024219819B2 (en) 2026-06-04
JP2023554405A (ja) 2023-12-27
AU2024219819A1 (en) 2024-10-10
CN116745291A (zh) 2023-09-12
AR124379A1 (es) 2023-03-22

Similar Documents

Publication Publication Date Title
JP7744538B2 (ja) N-(2-(4-シアノチアゾリジン-3-イル)-2-オキソエチル)-キノリン-4-カルボキサミド
US12624033B2 (en) KRAS inhibitors
AU2018351400B2 (en) Dihydropyrimidine compounds and uses thereof in medicine
US11236087B2 (en) Highly active pyrazolo-piperidine substituted indole-2-carboxamides active against the hepatitis B virus (HBV)
CN119301132A (zh) 用于治疗癌症的卤代吲哚大环化合物
RU2332412C2 (ru) Производные пиразола
BRPI0714359A2 (pt) inibidores de pirrolotriazina cinase
TW200831518A (en) Imidazothiazole derivatives
BR102015024618A2 (pt) compostos inibidores de quinase de ligação de tank
US11447479B2 (en) Compounds active towards nuclear receptors
TWI919070B (zh) 醯胺雜芳香族化合物及其用途
JP2020537671A (ja) ピリミジンTBK/IKKεインヒビター化合物およびそれらの使用
WO2015125785A1 (ja) 複数置換基を有するピラゾロン誘導体
JP2025525344A (ja) N-(2-(4-シアノチアゾリジン-3-イル)-2-オキソエチル)-キノリン-4-カルボキサミド
US20240317748A1 (en) Carbonyl substituted diazaspiro compounds and its use
JP2023508955A (ja) 脂質異常症の治療に適した新規な化合物
JP2009298713A (ja) イミダゾチアゾール誘導体
EA048482B1 (ru) N-(2-(4-цианотиазолидин-3-ил)-2-оксоэтил)хинолин-4-карбоксамиды
EA051853B1 (ru) N-(2-(4-цианотиазолидин-3-ил)-2-оксоэтил)хинолин-4-карбоксамиды
US20250122183A1 (en) Nitrogen-Linked Benzisoxazole Sulfonamide Derivatives
EA052200B1 (ru) Амидогетероароматические соединения, применимые в лечении заболеваний печени
WO2025202922A1 (en) Imidazopyridazine il-17 inhibitor compounds
CN121127467A (zh) 作为ripk1抑制剂的异噁唑烷及其用途
JP2026511536A (ja) メニンのアゴニズムを介してがんに対して作用する1-h-ピロロ[2,3-c]ピリジン化合物
EA050746B1 (ru) Карбонилзамещенные диазаспиросоединения и их применение

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241024

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241024

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20241024

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241217

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250115

R150 Certificate of patent or registration of utility model

Ref document number: 7622229

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150